Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MedReleaf Receives Health Canada Approval for Cannabis Softgel Capsules
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/06/MedReleaf-Receives-Health-Canada-Approval-for-Cannabis-Softgel-Capsules
MARKHAM, ON, Feb. 6, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced that it has received Health Canada approval for the sale of its cannabis oil softgel capsules, becoming the first licensed producer ("LP") to bring colour-coded and cannabis variety-specific softgel capsules to market and the only LP to manufacture softgel capsules from a certified ISO and GMP facility.
"Orally ingested softgel capsules give prescribing physicians and patients precise dosing in a familiar and convenient medicinal form factor. These products provide access to cannabis for an under-served patient community more comfortable taking their medication in a traditional capsule rather than by oil or through vapourizers," said Robert Gora, Senior Director of Physician Outreach. "As part of MedReleaf's ongoing focus on patient safety, our softgel capsules are uniquely colour-coded to allow patients to easily differentiate between the specific cultivar or type of oil product that they are consuming, letting patients more safely manage their medication."
"Our product development teams continue to set the standard for innovation and quality in our industry with pharmaceutical-grade softgel capsules that faithfully capture both cannabinoid and terpenes profiles of our award-winning varieties. The addition of softgel capsules to our product line will enhance our efforts to build physician support for medical cannabis and are more cost effective to produce, easier to swallow, and have a longer shelf-life than standard oil capsules," added Neil Closner, CEO of MedReleaf.
MedReleaf's softgel capsules will be categorized by four different colours. This colour colding ensures that patients will know the specific cultivar or type of oil product they are consuming:
Blue for indicas (nighttime)
Yellow for sativas (daytime)
Colourless for capsules without THC (CBD only)
Purple for balanced products (featuring both THC & CBD)
Production of MedReleaf's softgel capsules has begun and will be available for order in the following varieties in the coming weeks:
MedReleaf patients and health care professionals are encouraged to visit www.MedReleaf.com to find out more and to order product.
About MedReleaf Corp.
Voted Top Licensed Producer at the 2017 Lift Canadian Cannabis Awards, MedReleaf is an R&D-driven company dedicated to innovation, operational excellence and the production of top-quality cannabis. Sourced from around the world and carefully cultivated in one of two state of the art ICH-GMP and ISO 90001 certified facilities in Ontario, the Company delivers a variety of premium products for the global medical market and is committed to serving the therapeutic needs of its medical patients and providing a compelling product assortment for the adult-use recreational consumer.
For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleaf
Forward Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which are based upon MedReleaf's current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact.
Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, MedReleaf does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for MedReleaf to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in MedReleaf's Annual Information Form dated June 27, 2017 and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in MedReleaf's Annual Information Form could cause actual events or results to differ materially from those described in any forward-looking information.
great news, not sure why this board is empty. MedReleaf is a good one to own at this level.
Huge news out! MedReleaf receives Health Canada approval for cannabis oil softgel capsules
https://www.newswire.ca/news-releases/medreleaf-receives-health-canada-approval-for-cannabis-oil-softgel-capsules-672906993.html
Glad I bought the panic on Friday
MEDFF
And away we gooooo
News! MedReleaf Australia Commences Commercial Operations
https://www.newcannabisventures.com/medreleaf-australia-commences-commercial-operations/
LEAF
MEDFF
sold at the top but still has 8,826,665 shares. most likely brought it down to today's price
Tikun Olam Sells 1,000,000 shares of MedReleaf
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/01/30/Tikun-Olam-Sells-1000000-shares-of-MedReleaf
Toronto, Ontario--(Newsfile Corp. - January 30, 2018) - Tikun Olam Ltd. announces that on January 29, 2018 it sold over the Toronto Stock Exchange, 1,000,000 common shares (representing approximately 1.05% of the outstanding shares) of MedReleaf Corporation (TSX:LEAF). The shares were sold at a price of $22.02 per share for total gross consideration of $22,020,000. This press release is being issued pursuant to Canadian early warning requirements because Tikun Olam's ownership of shares has decreased to less than 10% of outstanding share capital of MedReleaf Corporation.
Tikun Olam now beneficially owns and controls 8,826,665 common shares representing approximately 9.31% of the outstanding share capital of MedReleaf on a non-diluted basis. Prior to the foregoing sale, Tikun Olam beneficially owned and controlled 9,826,665 common shares, representing approximately 10.36% of the outstanding shares of MedReleaf on a non-diluted basis.
The shares were sold for investment purposes. Tikun Olam has a long-term view of the investment and may acquire additional shares either on the open market or through private acquisitions or sell the shares either on the open market or through private dispositions in the future depending on market conditions, reformulation of plans and/or other relevant factors.
Tikun Olam is the first and largest supplier of medical Cannabis in Israel, and one of the leading medical cannabis companies in the world. It is also one of the founding shareholders of MedReleaf Corporation.
MedReleaf Corporation is located at Markham Industrial Park, P.O. Box 3040, Markham, Ontario, L3R 6G3. A copy of Tikun Olam's early warning report will appear on MedReleaf Corporation's profile on SEDAR at www.sedar.com and may also be obtained by contacting Tikun Olam Ltd. at +972 (3) 544-5860.
up past $40 by way of 13
no, up past $40
Which is the wrong move on growth stocks.
Value stocks u hold and forget...not these wild horsies
The 3 safest stocks:
This one, OGRMF and IVITF.
Not pumped, good value, low floats, no BS
MedReleaf Ready To Rumble: Positioned Well For Long-Term Growth
https://seekingalpha.com/article/4139354-medreleaf-ready-rumble-positioned-well-long-term-growth
New article. MedRel mentioned. Safest MJ stocks:
https://www.fool.com/investing/2018/01/22/the-safest-marijuana-stocks-to-buy-in-2018.aspx
America really fumbled this to Canada, good for you all
I live in Canada and there are a lot of baby boomers buying pot stocks and holding till July at the least when it becomes legal. Lots of folks at my work into LEAF TSX. People are attending Pot stock sessions here and they are no where near day traders lol. These guys are buying and holding no matter the ups and downs
Surprised more people are not weighing in on this stock. I got in at $^.79/share and did pretty well so far.
Complete Guide To The Cannabis Industry #1: Production Cost
Jan. 8, 2018 1:32 PM ET|
Includes: ACBFF, APHQF, CMMDF, MEDFF, PRMCF, TWMJF
Cornerstone Investments
Cornerstone Investments
Long/short equity, special situations, commodities, medium-term horizon
(626 followers)
Summary
Cash production cost is an important metric for cannabis industry.
Top cannabis producers report cash cost differently.
Aphria is the lowest cost producer while Aurora has the highest cash cost among top producers.
All amounts in C$ except otherwise noted; market data as of Friday, Jan 5.
We are excited to launch our Complete Guide to The Cannabis Industry series that aims to equip investors with the knowledge they will need to analyze cannabis companies and make informed investment decisions in this sector as Canada is heading for full legalization by July 2018. In this article, we will discuss production cost, a metric cited by many but few understand fully given the non-IFRS nature and different definitions employed by producers. We will examine the top 4 producers but also wanted to point out that most other producers still don't publish cash cost per gram (such as Kronos Group (MJN.TO) and CanniMed (CMED.TO)).
For the cannabis industry, production costs are important, given it is the single largest cost of producing cannabis. Management uses this measure to track production cost trends and assess the sensitivity and tolerance for pricing changes. For investors, it is important to understand which producers have cost advantage in order to help assess competitiveness and profitability. While the Canadian cannabis industry is still relatively new and investors are avidly awaiting full legalization in July 2018, we will try to break down the various cost metrics being reported by the top 4 Canadian producers based on market capitalization. While we can't analyze every cannabis company out there, we hope this article provides a useful and practical framework for investors to analyze any producers you find interesting going forward.
Follow us for more Cannabis industry analysis and investment ideas! Also, for a detailed overview of the Canadian marijuana industry and analysis on the market leader, Canopy Growth (OTCPK:TWMJF), take a look at our recent article "Canopy Growth: Best Way To Play the Cannabis Industry".
Canopy Growth (WEED.TO)
Canopy is the largest publicly traded cannabis company with a market capitalization of C$6.5 billion. Canopy calculates its weighted average cost per gram before harvest, post-harvest and after shipping and fulfilling:
Cost to harvest (from cloning to harvest): includes all the cash operating costs including growing, utilities, nutrients, rent, and allocated overheads.
Post-harvest costs: cash operating costs related to the production of value-added products, including oil and soft gel capsules. Also includes cash costs of trimming, milling, drying, lab and testing and allocated overheads.
Shipping and Fulfilling: cash cost related to delivery, royalties under licensing agreements (i.e. Snoop Dogg), packaging and materials
Source: company reports
During Q2 2018 that ended on September 30, 2017, Canopy reported cost per gram to harvest of $0.72, compared to $0.99 same period last year. As Canopy continues to bring additional capacity online and optimize operations, we would expect cost to continue trending lower over time.
Aurora Cannabis (OTCQX:ACBFF) (ACB.TO)
Aurora is the second largest publicly traded cannabis company with a market capitalization of C$6 billion. Aurora reports cash cost of sales per gram of dried cannabis and also cash cost to produce each gram, which is what we will focus on in this article for comparative purposes. The calculation is as following:
Cash cost of sales: IFRS production costs and removing the effect of changes in fair value of biological assets, non-cash production costs, oil conversion costs, cost of sales from service revenue, and purchases from other Licensed Producers. Notice that Aurora started with reported cost of sales per IFRS and then removed the impact of fair value adjustments and the impact of oil conversion and depreciation costs to arrive at cash cost, similar to other producers
Cash cost to Produce: cash cost of sales less packaging costs.
Source: Company reports
Aphria (OTCQB:APHQF) (APH.TO)
Aurora is the third largest publicly traded cannabis company with a market capitalization of C$3 billion. Aphria provides two metrics of cost per gram, "all-in" cost and cash costs per gram. The difference between the two metrics are amortization and packaging costs.
Production Costs (reported): Aphria's production costs include direct cost of materials and labour related to cannabis sold, including growing, cultivation, harvesting, QA, oil processing, packaging, labelling and amortization and PPE.
All-In Cost of Sales: Production costs less cost of accessories, oil conversion costs, and IFRS adjustments to inventory
Cash Cost to Produce: Cost of sales less amortization and packaging
Source: Company reports
MedReleaf (OTCPK:MEDFF) (LEAF.TO)
MedReleaf is the fourth largest cannabis company in Canada with a market capitalization of C$2.6 billion. MedReleaf calculates its cash cost per gram sold by removing post production costs from reported production costs:
Cash Production Cost: Reported production costs less all non-cash based costs (including amortization and inventory writedowns or impairments) and all post production costs
Post Production Costs: include indirect overhead expenses such as: equipment rentals, payment processing fees, indirect labour expenses, shipping and packaging expenses, cost of accessories sold, quality control expenses, and other order fulfillment costs included in production costs.
Source: Company reports. Note the typo in MedReleaf's disclosure above where "Amortization costs" should read "Production costs"
Compare Different Reporting Standards
Given the non-IFRS nature of cash cost to produce each gram, let's begin with a few observations on consistency and inconsistency across the 4 top producers we have examined:
All 4 companies calculate cost of production based on a cash basis. The calculation excludes non-cash adjustments under IFRS and other accrual expenses, which makes sense given the eccentric requirements under IFRS to record changes in fair value under cost of goods sold.
All 4 companies included cultivation costs related the production of cannabis, including growing, nutrients, utilities etc.
All 4 companies exclude packaging and shipping costs in their calculation of cash cost to produce.
Treatment for the following items differs among the 4 producers:
Oil Conversion Costs: Canopy is the only company that doesn't break out oil conversion costs while the other 3 producers excluded oil conversion costs to arrive at cost of dried cannabis. Canopy lumped oil conversion cost into post harvest costs and without breakdown of the constituents.
Total Grams: Aurora calculates cash cost per gram based on grams produced; others use grams sold.
MedReleaf: MedReleaf has the most different cash cost to produce among the top 4 producers. The company's reported cash costs exclude QA and indirect overhead. It is unclear whether post-harvest processing (trimming, sorting, lab and testing) is excluded, but most likely, yes, since QA is excluded in this case.
Below, we have summarized the key components of each company's reported cash cost to produce. In the case of Canopy, we are referring to its Cost per Gram Before Shipping and Fulfillment.
Source: Cornerstone Investments, Company reports
Putting It All Together
After we understand how each of the top 4 Cannabis produces report cash cost to produce dry cannabis, let's stack them up for a comparison. Before we reach any conclusion, let's review the limitations due to differences in how the reported cash cost is calculated.
Oil Processing: Canopy's reported cost before shipping and fulfillment and MedReleaf's reported cost to produce includes cost of oil processing, thus their production costs are overstated relative to Aphria and Aurora. Oil processing costs are not directly related to the cultivation of cannabis plant and represent a post-production value-add process. It is very difficult to adjust Canopy and MedReleaf's reported cash cost to exclude oil processing, given the limited information we have across disclosures from many produces. The disclosures are inadequate as most companies were small enterprises not long ago, and disclosure was not a priority.
An interesting observation is that in the latest quarter, Aphria's reported oil processing costs is $0.05 per gram, while Aurora's oil cost per gram was a whopping $1.42 per gram. Aurora did not disclose any more details around the extremely high oil conversion costs, so this is one of the red flags that we will continue to monitor and hopefully get an answer soon.
All-In Cost: We also calculated an "All-In Cost" that adds back packaging and fulfillment costs. We did not include depreciation and amortization, given that many companies are heavily investing in infrastructure that results in unusually high depreciation. Heavy M&A also results in high intangibles that result in higher amortization. We use all-in cost as a second proxy for overall costs of production and shipping.
Source: Cornerstone Investments, Company reports
We can make the following observations
Aphria has the lowest cost among the top 4 producers. Aphria's low production cost has become the industry standard, enabled by the adoption of greenhouse. By using greenhouses and natural light instead of indoor artificial light to produce its crop, Aphria benefited from more sunlight hours and improved growing techniques to slash its "all-in cost" as well.
Aurora has the highest cash cost, and its extremely high oil processing costs also stood out from the group. Aurora also differs from other producers by using total grams produced, instead of total grams sold to calculate cash cost. In Q1 2018, Aurora produced 1.0 million grams while only sold 0.9 million grams, thus lowering its reported cash cost because production costs are only recognized in the period sales are recorded.
Canopy has the second lowest cash cost, but its all-in cost is the highest due to high marketing, fulfilling, and royalty payments. Canopy is the industry leader in product branding, marketing, and licensing. For example, it has licensing deals with Snoop Dogg that adds to the all-in cost but forms an important part of Canopy's overall marketing strategy.
Conclusion
We can use cash cost to look into a company's production capabilities and also management style and accounting choices. We found out Aphria has the lowest cost due to its greenhouse adoption; Canopy has a competitive cash cost but spends a lot more money on marketing, licensing, and fulfillment than its peers; Aurora has the highest cash cost even after adopting aggressive accounting by using total grams produced instead of sold.
As producers improve disclosure and reporting ahead of legalization, cash cost of production will become a common metrics increasingly adopted by the industry. However, the cash cost calculation is expected to remain different among producers. We hope this article shed some lights on the major components of cash cost and examples of differences among producers' calculations. As the industry continues to evolve and production profile stabilizes, production cost will become ever more important.
That is a lot of ammo.
News! MedReleaf Corp. Announces $100.7 Million Bought Deal Financing
http://www.newswire.ca/news-releases/medreleaf-corp-announces-1007-million-bought-deal-financing-668430293.html
KAYS KAYS KAYS KAYS
RETAIL POT STORE
EXPANSION MODE
GROWTH POSSIBILITIES ENDLESS
BUFFALO WILD WINGS OF POT????
One day we shall see.....
exactly, hoping to get back in
Had a big run already like all Canada weed stocks. Missed this one and need to wait for a serious dip.
Got into this stock this week, It should get pretty wild from here to July when it becomes legal in Canada
Maybe that means its not a scam thats being pumped? im still learning OTC
KAYS! Pot Store sales growth ! Is going to blow past expectations!!!
KAYS
nice day for MEDFF today!!!! word needs to get out
one more for you, last one, good reading
The pure-play pot stock with the best operating margin might surprise you
While there's absolutely some guesswork at play here given the fact that recreational marijuana is still illegal in all but one country worldwide, my belief is that MedReleaf (NASDAQOTH:MEDFF) will eventually generate the best operating margin of all pure-play marijuana stocks.
MedReleaf offers a lot of the same growth tactics as its peers. It's a Canadian cannabis grower that's built up its eligible medical patient base, raised cash for expansion (albeit in its case it did so through an initial public offering, rather than through multiple bought-deal offerings), and worked to grow its capacity.
But MedReleaf has two advantages up its sleeve. First, it tends to hit a more affluent medical cannabis clientele, which could translate into bigger bucks if Canada approves adult-use weed by July 2018. More expensive cannabis strains generally mean higher margins.
Yet in the grand scheme of things, dried cannabis margins tend to underwhelm compared to other pot products. In particular, cannabis oils tend to have the best margins in the industry due to their considerably higher price point than dried cannabis. As of the end of 2016, MedReleaf controlled nearly 45% of Canada's cannabis oils market. This focus on consumers who want a higher-quality product should pay off in the form of the best operating margin, in my opinion.
If you're looking to add a marijuana stock to your watchlist, MedReleaf might be the name to consider.
After reading all this i jumped on, good luck to you
MedReleaf Corp. (OTC: MEDFF)
MedReleaf sets The Medical Grade Standard for cannabis in Canada and around the world. The first and only ISO 9001 certified cannabis producer in North America, MedReleaf is a R&D-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis. Sourced from around the world and perfected in one of two state of the art facilities in Ontario, MedReleaf delivers a variety of premium products to patients seeking safe, consistent and effective medical cannabis.
MedReleaf: 1,245% aggregate sales growth
Another Canadian pot stock with incredible sales growth is MedReleaf (NASDAQOTH:MEDFF), which went public earlier this year. In just two years, sales have grown from a little more than $2.3 million to $31.4 million as of 2017.
Like Aphria, MedReleaf has primarily focused on organic expansion opportunities. Whereas many of its peers have been diluting their shareholders with one bought-deal offering or convertible debt offering after another, MedReleaf has leaned on the bounty from its initial public offering to expand growing capacity at its Bradford facility.
What makes MedReleaf unique is the company's focus on considerably higher margin dried cannabis and cannabis products. MedReleaf offers pricier cannabis strains that cater to a more affluent clientele, as well as focuses its efforts on controlling a large portion of Canada's cannabis oils market. Oils are a higher-price-point, higher-margin item. In other words, MedReleaf can make more money while generating the same amount of revenue as its peers.
The company was also healthfully profitable in 2016 and 2017, and compared to other pot stocks may be the most undervalued of them all. If Canada moves forward with recreational legalization, MedReleaf could be in line to garner about 10% market share.
If you're looking for potential success story in the marijuana industry, these are three to consider.
This might be the only undervalued marijuana stock
However, one pot stock might actually be undervalued, even taking into account the fact that it's doubled since the end of July. Ladies, gentlemen, and marijuana-stock investors, say hello to Canada's MedReleaf (NASDAQOTH:MEDFF).
If the name isn't all that familiar, it's because the company only went public earlier this year. It's a medical cannabis play in Canada that, like Aurora, is itching for Canada's parliament to legalize recreational marijuana. Among the big four companies in our neighbor to the north, MedReleaf has an opportunity to garner perhaps 10% of both the medical and recreational market share (assuming approval).
What's been really notable about MedReleaf, with the exception of its most recent quarter, is that it's been significantly more profitable than its peers. This is a result of the company focusing its efforts on a more affluent medical clientele in Canada. It offers a more expansive array of cannabis strain prices, and has really pushed into cannabis oils and extracts as a source of sales growth. Cannabis oils and extracts have considerably higher price points relative to dried cannabis, meaning they also lead to better margins (MedReleaf controlled 44.5% of the Canadian cannabis oils market share as of the end of 2016). This means MedReleaf doesn't have to work nearly as hard as its peers to generate the same amount of profit.
A bottle of cannabis oil next to a cannabis leaf.
Image source: Getty Images.
The company also ended its most recent quarter with about $58 million in cash and cash equivalents. Though that's dwarfed by the more than $268 million Aurora Cannabis has in its coffers, MedReleaf has been much more responsible about its capital raises. Rather than diluting its shareholders, MedReleaf has been living off the capital raised from its initial public offering. This doesn't mean it won't seek a bought-deal offering like its peers in the future, but it does suggest that management may have a better focus on its shareholders than its peers.
With MedReleaf having a genuine opportunity to lead the industry with the highest operating margin, it could easily be undervalued if Canada moves forward with adult-use legalization and it secures about 10% of the medical and recreational market.
medff
2. MedReleaf
MedReleaf ranks behind Canopy Growth in current sales. I view the marijuana stock as a good pick for 2018 largely for the same reasons that I think Canopy will go higher next year.
Production capacity is likely to be paramount in 2018, assuming legalization of recreational marijuana goes as planned. I suspect that every marijuana grower in Canada will be able to sell as much as they can produce. Since April, MedReleaf has boosted its capacity by 80%. MedReleaf's production costs are also quite low, which means a nice chunk of increased revenue will flow right to the bottom line.
MedReleaf recently raised more cash through a stock offering. Acquisitions of smaller marijuana growers seem likely, in my opinion. I also think that MedReleaf could catch the eye of some of Constellation Brands' peers. The company has already identified beer and other beverages as part of its growth strategy. I wouldn't be surprised at all if MedReleaf snags a big deal in 2018 along the lines of the Constellation-Canopy partnership.
[url]https://www.fool.com/investing/2017/12/17/top-marijuana-stocks-to-buy-in-2018.aspx?source=djc&utm_campaign=article&utm_medium=feed&utm_source=djc
[/url][tag]medff[/tag]
Let’s get this board going! We have a good company here! Long and strong!
💸💸💸#MedReleaf Corp. Announces $100.5 #Million Bought Deal #Financing 💸💸💸 #LEAF #MEDFF #Canada #Cannabis https://t.co/ZSf5kw7ijB
— Technical420 (@Technical420) November 14, 2017
5.58 right before the conference ;)
nice vision :)
nice vision :)
I just bought it on a hunch at 6.79 a share. Made out pretty well.
It's a good thing i suppose. When this starts getting more interest, it will take off even further :)
I wonder if there's another message board it's on?? I don't get it either... what a run. I just bought a bunch of ACBFF today but am looking for a buying opp here. Sounds insane but the chart is setting up for $30 +
Mark Your Calendars - Upcoming MedReleaf Q2 Earnings
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2017/10/27/LEAF-MEDFF-Mark-Your-Calendars---Upcoming-MedReleaf-Q2-Conference-Call
Investors in marijuana releated stocks should always keep an eye out for earnings releases and conference calls regarding the companies they're holding in their portfolio. Whether you're an existing or prospective investor in MedReleaf Corp. (TSX:LEAF) (OTC:MEDFF), you should mark the company's upcoming earnings release in your calendar.
MedReleaf Corp. will be holding a conference call to discuss its second quarter fiscal 2018 results on Monday, November 13, 2017 at 8:00 A.M. EST. before the North American market open. The call will be hosted by Neil Closner, Chief Executive Officer, and Igor Gimelshtein, Chief Financial Officer, followed by a question and answer period. MedReleaf will be reporting its financial results in the morning prior to the call.
To access the call, dial in to 1-647-427-7450 or 1-888-231-8191. Also, the call will be live webcast via this link. Replays of the call will be available until November 20, 2017, and can be accessed by dialing in to 1-855-859-2056 with the password 9796804.
Yeah, I got 7000 shares of twmjf to. Wait until next year and this all will look great.
MEDFFs performance has outpaced them. I’ve been watching both and a few others but MEDFF seems to be leading the pack.
Followers
|
20
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
161
|
Created
|
06/26/17
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |